Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

401 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
p-53 gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial.
Di Leo A, Tanner M, Desmedt C, Paesmans M, Cardoso F, Durbecq V, Chan S, Perren T, Aapro M, Sotiriou C, Piccart MJ, Larsimont D, Isola J; TAX 303 translational study team. Di Leo A, et al. Among authors: sotiriou c. Ann Oncol. 2007 Jun;18(6):997-1003. doi: 10.1093/annonc/mdm075. Epub 2007 Mar 17. Ann Oncol. 2007. PMID: 17369602 Free article. Clinical Trial.
New data on chemotherapy in the adjuvant setting.
Piccart MJ, Sotiriou C, Cardoso F. Piccart MJ, et al. Among authors: sotiriou c. Breast. 2003 Dec;12(6):373-8. doi: 10.1016/s0960-9776(03)00139-5. Breast. 2003. PMID: 14659108
Targeting the ubiquitin-proteasome pathway in breast cancer.
Cardoso F, Ross JS, Picart MJ, Sotiriou C, Durbecq V. Cardoso F, et al. Among authors: sotiriou c. Clin Breast Cancer. 2004 Jun;5(2):148-57. doi: 10.3816/cbc.2004.n.020. Clin Breast Cancer. 2004. PMID: 15245620 Review.
Topoisomerase-II alpha expression as a predictive marker in a population of advanced breast cancer patients randomly treated either with single-agent doxorubicin or single-agent docetaxel.
Durbecq V, Paesmans M, Cardoso F, Desmedt C, Di Leo A, Chan S, Friedrichs K, Pinter T, Van Belle S, Murray E, Bodrogi I, Walpole E, Lesperance B, Korec S, Crown J, Simmonds P, Perren TJ, Leroy JY, Rouas G, Sotiriou C, Piccart M, Larsimont D. Durbecq V, et al. Among authors: sotiriou c. Mol Cancer Ther. 2004 Oct;3(10):1207-14. Mol Cancer Ther. 2004. PMID: 15486187 Clinical Trial.
401 results